GeneRx is a decision support tool covering over 100 different drug substances which have been found to be affected by the genetic variation in enzyme metabolic rates. Pharmacogenetic tests allow physicians to select the right drugs with the right dosage according to the patient's individual genotype. GeneRx helps the physician to identify the cases, in which genetic testing is recommended, and gives clear instructions on how to interpret the genetic test results.

Database contents:

  • Active ingredient, ATC code(s), generic drug name
  • Genetic variations related to the drug
  • Information about the phenotype affected, e.g. metabolic rate
  • Recommendation texts, e.g. dosing recommendations
  • References
  • Available genetic tests and their indications
  • Genetic test providers, contact information and ordering instructions

Database selection criteria

Abomics GeneRx Database is a collection of recommendations for the most clinically relevant and actionable pharmacogenetic drug-gene pairs. The contents of the database reflect, to some extent, published expert opinion pharmacogenetic recommendations and contents of commercial pharmacogenetic test panels. Clinical actionability of certain known drug-gene pairs is less obvious due to insufficient scientific evidence. Various pharmacogenetic test panels include many genes with a lot of published variations but with controversial or unrepeated results. As the database is intended to be directly implemented in clinical use, the included genes are primarily those which have drug recommendations with sufficient scientific evidence and high clinical relevance. The database is neither fully exclusive nor inclusive, and is subject to change as new literature is published.

Update protocols

The database is fully updated at least every fourth month. New published literature for each gene-drug pair is reviewed, and recommendations are changed when needed. New genes and drugs for existing genes are also included on every update cycle.

Recommendations are mostly based on published expert opinions and pharmacogenetic recommendation articles, e.g. by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Abomics medical advisors also review the literature published after the publication of these major articles, and the recommendations may be modified if new information warrants this. The FDA’s list of pharmacogenetic biomarkers in drug labels is also followed for update process. Recommendations are thus based on published, citable articles and drug labels or SPC (summary of product characteristics) documents, but reflect the synthesis of information by Abomics medical advisors. The clinical decision for drug dosing for each patient is, however, on physician’s responsibility.

Clinical significance

A Pharmacogenetic factors do not have significant effect on drug effectiveness or adverse reactions.
B Drug effectiveness or adverse reactions may have pharmacogenetic variation, but the clinical significance is low for most patients. Monitor drug response and possible adverse reactions. If genetic test result is available, consider changing drug or dosing based on result.
C Drug effectiveness or adverse reactions are having pharmacogenetic variation with intermediate relevance. If genetic test result is available, consider changing drug or dosing based on result. If genetic test has not been conducted, consider ordering test.
D Drug effectiveness or adverse reactions are having pharmacogenetic variation with significant relevance. Order genetic test, or check existing test result before prescribing drug. Check dosing and administration based on test result.

Level of evidence

0 Level of evidence not defined.
1 Published incomplete case reports or product information, or deduction based on studies with similar drugs.
2 Published case reports, well documented.
3 Published controlled studies.
4 Published controlled studies of good quality.
Send feedback

Sales & Support

Abomics

Abomics Oy
Tykistökatu 4 B
FI-20520 Turku
info@abomics.fi
www.abomics.fi